Healthcare
Live Price
Offline$0.05
+0.00% today
1Y Change
-73.68%
Window
Jun 23, 2025 → Jun 18, 2026
Coverage: 249 bars · Jun 23, 2025 → Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Immutep Limited (PRRUF) is a Healthcare stock with a market cap of $90.00M and listed on OTC. The stock last traded around $0.05 and down 73.7% across the available one-year price window (Jun 23, 2025 → Jun 18, 2026). Baseline metrics include revenue growth of +31.3%, EPS growth of -18.5%, a dividend yield of 0.0%. What stands out right now is revenue +31.3%, EPS -18.5%, free cash flow -73.7% with operating margin -2052.2% and ROIC -122.1%. Valuation already assumes a fairly strong business story at price/sales 15.0. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines PRRUF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
PRRUF
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
PRRUF Max Drawdown
-87.50%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for PRRUF and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$3.9M
+2167.3% YoY
FY Net Income
-$29.9M
+7.2% YoY
Free Cash Flow
-$17.7M
+41.6% YoY
Revenue Growth
+31.3%
EPS Growth
-18.5%
Gross Margin
-522.6%
Net Margin
-1404.1%
Income statement
AUD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 5M | 4M | 4M | 170K | 4M |
| Gross Profit | -56M | -38M | 1M | -27M | -13M |
| Operating Income | -126M | -88M | -78M | -34M | -32M |
| EBITDA | -63M | -45M | -40M | -32M | -18M |
| Net Income | -61M | -43M | -40M | -32M | -30M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
AUD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 67M | 162M | 123M | 80M | 60M |
| Total Assets | 157M | 202M | 147M | 102M | 82M |
| Total Liabilities | 13M | 12M | 11M | 8M | 9M |
| Shareholder Equity | 144M | 190M | 136M | 94M | 73M |
| Total Debt | 2M | 2M | 1M | 2M | 3M |
| Net Debt | -66M | -160M | -122M | -78M | -57M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
18M
+41.6% YoY
Capital Expenditures
16K
+31.9% YoY
Free Cash Flow
18M
+41.6% YoY
Key ratios
Gross Margin
-522.6%
Operating Margin
-2052.2%
Net Margin
-1404.1%
ROE
-69.2%
Debt / Equity
0.02x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.